Recursion Pharmaceuticals, Inc.
RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.00
Price-1.32%
-$0.04
1Y
Price
Market Cap
$1.574b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-2728.6%
EBITDA Margin-3135.3%
Net Profit Margin-2272.5%
Free Cash Flow Margin-2728.6%
EBITDA Margin-3135.3%
Net Profit Margin-2272.5%
Free Cash Flow MarginRevenue
$66.288m
-26.0%
1y CAGR+6.2%
3y CAGR+78.9%
5y CAGREarnings
-$559.778m
-54.3%
1y CAGR-44.2%
3y CAGR-40.3%
5y CAGREPS
-$1.20
-6.5%
1y CAGR-9.9%
3y CAGR-14.8%
5y CAGRBook Value
$1.025b
$1.340b
Assets$314.753m
Liabilities$72.375m
DebtDebt to Assets
5.4%
-0.1x
Debt to EBITDAFree Cash Flow
-$325.847m
-20.2%
1y CAGR-64.2%
3y CAGR-38.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company